Last checked at 18 Nov 2019 07:00
18 November 2019 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Notification of Interim Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2019 on Friday 6 December 2019.
A meeting for analysts will be held at 09.30am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 09.30am on the day of the results:
https://webcasting.buchanan.uk.com/broadcast/5dcc32879535b1405a05b0bd
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
ENDS
Contacts:
ReNeuron |
+44 (0) 20 3819 8400 |
Olav Hellebø, Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan (UK Media/Investor Relations) |
+44 (0) 20 7466 5000 |
Mark Court, Tilly Abraham | |
Argot Partners (US Media/Investor Relations) Claudia Styslinger, David Rosen |
+1 212 600 1902 |
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Jonathan Senior, Stewart Wallace, Ben Maddison | +44 (0) 20 7710 7600
|
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Mia Gardner |
+44 (0) 20 7496 3000 |
|
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.